Open for inclusion

A Phase II, Open-label, Study in Subjects with BRAF V600E Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib

Cancer type: Multiple diagnosis

Phase: II

Principal Investigator: Brunsvig Paal

Country: NO

Keywords: Norway, Oslo, BRAF V600E mutated, Rare Cancers, Dabrafenib, Trametinib

Status: Open for inclusion

Link to Clinicaltrials.gov: http://clinicaltrials.gov/ct2/show/NCT02034110?term=several+histologies&rank=1